

AMENDMENTS TO THE CLAIMS:

1. (Original) A method of inducing apoptosis in mammalian cells expressing Apo-2 receptor comprising exposing mammalian cells expressing Apo-2 receptor to an effective amount of an Apo-2 agonist antibody.
2. (Original) The method of claim 1 wherein said Apo-2 agonist antibody is a monoclonal antibody.
3. (Original) The method of claim 1 wherein said agonist antibody is a chimeric antibody.
4. (Original) The method of claim 1 wherein said agonist antibody is a humanized antibody.
5. (Original) The method of claim 1 wherein said agonist antibody is a human antibody.
6. (Original) The method of claim 2 wherein said monoclonal antibody is produced by the hybridoma deposited as ATCC HB-12456.
7. (Original) The method of claim 2 wherein said monoclonal antibody is produced by the hybridoma deposited as ATCC HB-12534.
8. (Original) The method of claim 2 wherein said monoclonal antibody is produced by the hybridoma deposited as ATCC HB-12536.
9. (Original) The method of claim 2 wherein said monoclonal antibody is produced by the hybridoma deposited as ATCC HB-12535.
10. (Original) A method of treating cancer, comprising exposing mammalian cancer cells to an effective amount of an Apo-2 agonist antibody.

11. (Original) The method of claim 10, wherein said cancer cells are lung cancer cells.
12. (Original) The method of claim 10, wherein said cancer cells are colon cancer cells.
13. (Original) The method of claim 10, wherein said cancer cells are glioma cells.
14. (New) A method of inducing apoptosis in mammalian cells expressing Apo-2 receptor comprising exposing mammalian cells expressing Apo-2 receptor to an effective amount of an Apo-2 agonist antibody which (a) binds to Apo-2 polypeptide consisting of the contiguous amino acid residues 1 to 411 of SEQ ID NO:1 and (b) stimulates apoptosis in at least one type of mammalian cell *in vivo* or *ex vivo*.
15. (New) The method of claim 14 wherein said Apo-2 agonist antibody is a monoclonal antibody.
16. (New) The method of claim 14 wherein said agonist antibody is a chimeric antibody.
17. (New) The method of claim 14 wherein said agonist antibody is a humanized antibody.
18. (New) The method of claim 14 wherein said agonist antibody is a human antibody.
19. (New) The method of claim 14 wherein said mammalian cells expressing Apo-2 receptor are cancer cells.
20. (New) The method of claim 19 wherein said cancer cells are lung cancer cells.

21. (New) The method of claim 19 wherein said cancer cells are colon cancer cells.

22. (New) The method of claim 19 wherein said cancer cells are glioma cells.

23. (New) A method of inducing apoptosis in mammalian cells expressing Apo-2 receptor comprising exposing mammalian cells expressing Apo-2 receptor to an effective amount of an Apo-2 agonist antibody which (a) binds to a soluble extracellular domain sequence of an Apo-2 polypeptide which consists of amino acid residues 54 to 182 of SEQ ID NO:1 and (b) stimulates apoptosis in at least one type of mammalian cell *in vivo* or *ex vivo*.

24. (New) The method of claim 23 wherein said Apo-2 agonist antibody is a monoclonal antibody.

25. (New) The method of claim 23 wherein said agonist antibody is a chimeric antibody.

26. (New) The method of claim 23 wherein said agonist antibody is a humanized antibody.

27. (New) The method of claim 23 wherein said agonist antibody is a human antibody.

28. (New) The method of claim 23 wherein said mammalian cells expressing Apo-2 receptor are cancer cells.

29. (New) The method of claim 28 wherein said cancer cells are lung cancer cells.

30. (New) The method of claim 28 wherein said cancer cells are colon cancer cells.

31. (New) The method of claim 28 wherein said cancer cells are glioma cells.

32. (New) A method of treating cancer, comprising exposing mammalian cancer cells to an effective amount of an Apo-2 agonist antibody which (a) binds to Apo-2 polypeptide consisting of the contiguous amino acid residues 1 to 411 of SEQ ID NO:1 and (b) stimulates apoptosis in at least one type of mammalian cancer cell *in vivo* or *ex vivo*.

33. (New) The method of claim 32 wherein said Apo-2 agonist antibody is a monoclonal antibody.

34. (New) The method of claim 32 wherein said agonist antibody is a chimeric antibody.

35. (New) The method of claim 32 wherein said agonist antibody is a humanized antibody.

36. (New) The method of claim 32 wherein said agonist antibody is a human antibody.

37. (New) The method of claim 32 wherein said mammalian cancer cells are lung cancer cells.

38. (New) The method of claim 32 wherein said mammalian cancer cells are colon cancer cells.

39. (New) The method of claim 32 wherein said mammalian cancer cells are glioma cells.

40. (New) A method of treating cancer, comprising exposing mammalian cancer cells to an effective amount of an Apo-2 agonist antibody which (a) binds to a soluble extracellular domain sequence of an Apo-2 polypeptide which consists of amino acid residues 54 to 182 of SEQ ID NO:1 and (b) stimulates apoptosis in at least one type of mammalian cell *in vivo* or *ex vivo*.

41. (New) The method of claim 40 wherein said Apo-2 agonist antibody is a monoclonal antibody.

42. (New) The method of claim 40 wherein said agonist antibody is a chimeric antibody.

43. (New) The method of claim 40 wherein said agonist antibody is a humanized antibody.

44. (New) The method of claim 40 wherein said agonist antibody is a human antibody.

45. (New) The method of claim 40 wherein said mammalian cancer cells are lung cancer cells.

46. (New) The method of claim 40 wherein said mammalian cancer cells are colon cancer cells.

47. (New) The method of claim 40 wherein said mammalian cancer cells are glioma cells.